These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7048047)

  • 1. Release of endotoxic lipopolysaccharide by sensitive strains of Escherichia coli submitted to the bactericidal action of human serum.
    Demonty J; De Graeve J
    Med Microbiol Immunol; 1982; 170(4):265-77. PubMed ID: 7048047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of purified lipopolysaccharide on the bactericidal reaction of human serum complement.
    Allen RJ; Scott GK
    J Gen Microbiol; 1980 Mar; 117(1):65-72. PubMed ID: 6993628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal, bacteriolytic and opsonic activity of human serum against Escherichia coli.
    Rozenberg-Arska M; Porsius JC; Jaarsma EY; Verhoef J
    J Med Microbiol; 1986 Sep; 22(2):143-9. PubMed ID: 3528498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lipopolysaccharide and complement in susceptibility of Escherichia coli and Salmonella typhimurium to non-immune serum.
    Tomás JM; Ciurana B; Benedí VJ; Juarez A
    J Gen Microbiol; 1988 Apr; 134(4):1009-16. PubMed ID: 3053980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
    Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
    Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum.
    Hill AW; Shears AL; Hibbitt KG
    Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of O-antigenic polysaccharide of Escherichia coli on endotoxin neutralizing activity of lysozyme.
    Liang AH; Sugawara N; Ohno N; Adachi Y; Yadomae T
    FEMS Immunol Med Microbiol; 1998 May; 21(1):79-87. PubMed ID: 9657324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bactericidal activity of normal human serum against Enterobacteriaceae rods with lipopolysaccharides possessing O-antigens composed of mannan.
    Tichaczek-Goska D; Witkowska D; Cisowska A; Jankowski S; Hendrich AB
    Adv Clin Exp Med; 2012; 21(3):289-99. PubMed ID: 23214191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human serum complement requirements for bacterial killing and protoplast lysis of Escherichia coli ML308 225.
    Allen RJ; Scott GK
    J Gen Microbiol; 1981 Mar; 123(1):179-81. PubMed ID: 7033454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.
    O'Hara AM; Moran AP; Würzner R; Orren A
    Immunology; 2001 Mar; 102(3):365-72. PubMed ID: 11298837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinetic study of the bacteriolytic and bactericidal action of human serum.
    Glynn AA; Milne CM
    Immunology; 1967 Jun; 12(6):639-53. PubMed ID: 5338688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains.
    Schiller NL
    Infect Immun; 1988 Mar; 56(3):632-9. PubMed ID: 3125110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased antibacterial activity against Escherichia coli in bovine serum after the induction of endotoxin tolerance.
    Hill AW; Shears AL; Hibbitt KG
    Infect Immun; 1976 Jul; 14(1):257-65. PubMed ID: 780275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme.
    Martinez RJ; Carroll SF
    Infect Immun; 1980 Jun; 28(3):735-45. PubMed ID: 6156906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelationship between serum beta-lysin, lysozyme, and the antibody-complement system in killing Escherichia coli.
    Donaldson DM; Roberts RR; Larsen HS; Tew JG
    Infect Immun; 1974 Sep; 10(3):657-66. PubMed ID: 4609906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram-negative sepsis.
    Chong KT; Huston M
    J Infect Dis; 1987 Nov; 156(5):713-9. PubMed ID: 3309071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective role of smooth lipopolysaccharide in the serum bactericidal reaction.
    Reynolds BL; Pruul H
    Infect Immun; 1971 Dec; 4(6):764-71. PubMed ID: 5005315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.
    Levy O; Ooi CE; Elsbach P; Doerfler ME; Lehrer RI; Weiss J
    J Immunol; 1995 May; 154(10):5403-10. PubMed ID: 7730641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic-induced release of endotoxin from bacteria in vitro.
    Crosby HA; Bion JF; Penn CW; Elliott TS
    J Med Microbiol; 1994 Jan; 40(1):23-30. PubMed ID: 8289210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.